Recent advances in trophoblast cell-surface antigen 2 targeted therapy for solid tumors.

Shutan Liao, Bing Wang, Rong Zeng, Haifeng Bao, Xiaomin Chen, Rakesh Dixit, Xiaoyan Xing

Drug development research 2021 Dec

filter terms:

Trophoblast cell-surface antigen 2 (Trop 2) is a transmembrane glycoprotein that is highly expressed in various cancer types with relatively low or no baseline expression in most normal tissues. Its overexpression is associated with tumor growth and poor prognosis; Trop 2 is, therefore, an ideal therapeutic target for epithelial cancers. Several Trop 2 targeted therapeutics have recently been developed for the treatment of cancers, such as anti-Trop 2 antibodies and antibody-drug conjugates (ADCs), as well as Trop 2-specific cell therapy. In particular, the safety and clinical benefit of Trop 2-based ADCs have been demonstrated in clinical trials across multiple tumor types, including those with limited treatment options, such as triple-negative breast cancer, platinum-resistant urothelial cancer, and heavily pretreated non-small cell lung cancer. In this review, we elaborate on recent advances in Trop 2 targeted modalities and provide an overview of novel insights for future developments in this field. © 2021 Wiley Periodicals LLC.

Citation

Shutan Liao, Bing Wang, Rong Zeng, Haifeng Bao, Xiaomin Chen, Rakesh Dixit, Xiaoyan Xing. Recent advances in trophoblast cell-surface antigen 2 targeted therapy for solid tumors. Drug development research. 2021 Dec;82(8):1096-1110